The patented use of CarnoSyn beta-alanine has led to significant advancements in muscle performance technology
Conclusions: YM selectively upregulates GLP-1 pathways without affecting GIP, likely through gut-mediated mechanisms
Information gathered included demographics, medical histories, medication use, signs and symptoms of hypogonadism, and assessments of depressive symptoms and/or a known diagnosis of depression or use of an antidepressant
Our analysis suggests greater efforts are needed to increase access and adherence for patients without type 2 diabetes and those with lower incomes
The design of this single-arm trial precludes the inference of a causal relationship between mecasermin and growth and harms outcomes
If the employer carved out anti-obesity drugs, that is a benefit exclusion not a medical-necessity denial and is not appealable through PA